US · Healthcare · Biotechnology
EPS came in at -0.08 against a street estimate of -0.07 — a miss of 14.3%.
Analysts rate Maravai Lifesciences Holdings Inc a buy (5 buy, 4 hold, 0 sell out of 9) with an average price target of $8.50.
CONFIDENT Q2 revenue $51.4M (+9% YoY) with TriLink up 12%, Cygnus +3%. Adjusted EBITDA $8.7M, margins expanded 1,600bps. Debt cut in half to $147M. Raised FY26 EBITDA guidance to $33–35M but held revenue guide due to lumpy GMP/CDMO orders. Q2 2026 New China patent for CleanCap capping analogs reinforces global IP. China market small but focus area. Analysts pressed on revenue guide conservatism vs. strong run-rate business; management reaffirmed lumpy GMP/CDMO orders cannot be modeled. Questioned ModTail and enzyme timing; management confirmed no 2026 revenue, 2027 upside. Validated sustainability of TriLink double-digit growth via demand signals and clinical trial funnel expansion. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| GTCR LLC | 13.52% |
| BlackRock Inc | 6.69% |
| BRAIDWELL LP | 5.84% |
| Arnhold & S. Bleichroeder Advisers, LLC | 4.93% |
| 12 West Capital Management LP | 4.74% |
| Millennium Management LLC | 4.37% |
| Vanguard Capital Management, LLC | 3.55% |
| Ophir Asset Management Pty Ltd | 3.24% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $45,851 thousand, up from $41,630 thousand in the third quarter of 2025. • Nine-month 2026 revenue | 2026-11-05 |
| Current report · Q4 2026 OTHER NOTABLE POINTS • Maravai LifeSciences Holdings, Inc. reported its third-quarter 2026 financial results on November 4, 2026. • The results anno | 2026-11-04 |
| Quarterly report · Q2 2026 MARAVAI LIFESCIENCES HOLDINGS, INC. - 10-Q SUMMARY HEADLINE NUMBERS • Revenue (6M 2026): $117.3 million vs. $94.2 million (2025) — up 24% • Revenue | 2026-08-07 |
| Results announced · Q3 2026 MARAVAI LIFESCIENCES Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $51.4 million, up 8.5% year-over-year from $47.4 million in | 2026-08-06 |
| Material agreement · Q2 2026 MARAVAI LIFESCIENCES HOLDINGS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company refinanced its debt on June 2, 2026, replacing prior credit facili | 2026-06-03 |
| Shareholder vote results · Q2 2026 MARAVAI LIFESCIENCES HOLDINGS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Total shares outstanding (as of March 27, 2026): 258,180,170 shares - Cl | 2026-05-29 |
| Quarterly report · Q1 2026 MARAVAI LIFESCIENCES HOLDINGS, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue: $65.8 million (Q1 2026) vs. $46.9 million (Q1 2025) — increas | 2026-05-08 |
| Results announced · Q2 2026 MARAVAI LIFESCIENCES Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $65.8 million, up 40.5% year-over-year from $46.9 million in Q1 2 | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Maravai Lifesciences Holdings Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.